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Despite extensive research, the development of an effective malaria vaccine remains
elusive. The induction of robust and sustained T cell and antibody response by
vaccination is an urgent unmet need. Chimeric virus-like particles (VLPs) are a promising
vaccine platform. VLPs are composed of multiple subunit capsomeres which can
be rapidly produced in a cost-effective manner, but the ability of capsomeres to
induce antigen-specific cellular immune responses has not been thoroughly investigated.
Accordingly, we have compared chimeric VLPs and their sub-unit capsomeres for
capacity to induce CD8+ and CD4+ T cell and antibody responses. We produced
chimeric murine polyomavirus VLPs and capsomeres each incorporating defined CD8+
T cell, CD4+ T cell or B cell repeat epitopes derived from Plasmodium yoelii CSP.
VLPs and capsomeres were evaluated using both homologous or heterologous DNA
prime/boost immunization regimens for T cell and antibody immunogenicity. Chimeric
VLP and capsomere vaccine platforms induced robust CD8+ T cell responses at similar
levels which was enhanced by a heterologous DNA prime. The capsomere platform was,
however, more efficient at inducing CD4+ T cell responses and less efficient at inducing
antigen-specific antibody responses. Our data suggest that capsomeres, which have
significant manufacturing advantages over VLPs, should be considered for diseases
where a T cell response is the desired outcome.
Keywords: malaria, vaccine, T cells, virus-like particle, capsomere, murine polyomavirus, chimeric,
Plasmodium yoelii
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INTRODUCTION
The annual mortality rate of malaria is currently estimated at
405,000 people of whom 67% are children under 5 years of
age (1). Eliminating the causative Plasmodium spp. parasite will
likely require an effective vaccine (2) but conventional sub-unit
vaccines strategies have thus far proved to be suboptimal. The
identification and development of vaccine delivery platforms
which induce long-lasting robust cellular and antibody immune
responses is a global health priority. A specific goal is a
vaccine against the pre-erythrocytic (sporozoite/liver) stage of
Plasmodium sporozoites which would prevent both the clinical
symptoms which develop during the blood stage, and the
transmission of the diseases which occurs during the sexual stage.
The most advanced malaria vaccine candidate, RTS,S (also
known as MosquirixTM), is a virus-like particle (VLP) comprising
multiple copies of the P. falciparum circumsporozoite protein
(PfCSP) B cell repeats and some CD4+ and CD8+ T cell epitopes
fused with recombinant hepatitis B surface antigen (RTS) and
co-expressed with free hepatitis B surface antigen (S) (3), co-
administered with AS01 adjuvant (4). However, although early
clinical studies showed some protective efficacy in the first
year after vaccination, it is now established that RTS,S induced
protection is low and wanes quickly (5, 6). Significant research
efforts have been directed at either improving the vaccine
platform, or incorporating additional antigens to broaden the
protective immune response. Additionally, ease and cost of
manufacturing is an important consideration.
VLPs are formed when recombinant viral structural proteins
assemble into a highly repetitive array which resembles the native
form of the virus. These units contain no genomic material so
are incapable of replication, but they are highly immunogenic
and particularly good at inducing antibody responses without
the need for additional adjuvants (7–9). VLP vaccines that have
been licensed include hepatitis B virus and human papillomavirus
where protection is mediated through neutralizing antibodies
(10, 11). In those VLPs, the entire structural protein comes
from the pathogen itself and their structure resembles the
cognate native virus targeted by the vaccine. However, instead,
a generic VLP independent of the pathogen target can be used
to produce a chimeric VLP with antigenic epitopes inserted into
regions of a flexible carrier virus, thereby making a vaccine
platform which can theoretically target any organism [reviewed
in (12–14)]. Chimeric VLPs have been shown to be effective at
inducing robust antibody responses (12–14), but their efficacy
in generating cellular responses has not been comprehensively
investigated. In vitro studies have shown that chimeric hamster
polyomavirus and SV40 VLPs incorporating T cell epitopes from
mucin 1 and influenza, respectively, can induce activation of
epitope-specific CD8+ T cells (15, 16). Further evidence of CD8+
T cell induction was reported using hamster polyomavirus in
a mouse study which demonstrated in vivo clonal proliferation
of transferred epitope-specific CD8+ T cells, tumor growth
inhibition and protection from lymphocytic choriomeningitis
virus (17). We recently reported that immunization of mice
with murine polyomavirus incorporating defined T cell epitopes
derived from the P. yoelii CSP antigen (PyCSP) induced robust
CD8+ T cell responses as well as high antibody titres, but poor
CD4+ T cell responses (18).
Murine polyomavirus VLPs are generated when VP1
structural proteins form pentameric capsomeres (19) which
can then be chemically induced in vitro to self-assemble into
a highly repetitive VLP containing 72 capsomeres (7, 9, 20).
The crystal structure of the VP1 protein has been previously
described (21) as well as the predicted structures of chimeric
capsomeres and VLPs with the Group A Streptococcus J8 peptide
epitopes (7). The formation of VLPs from the subunit capsomere
components adds time and cost to vaccine production (22). Also,
the introduction of foreign epitopes could interfere with the
structural formation of the VLPs. These shortcomings could be
overcome if the chimeric capsomeres themselves were sufficiently
immunogenic so that the subsequent VLP production steps were
not required. To address this, our colleagues constructed a
truncated MuPy-VP1 which prevented the formation of VLPs,
and further modified the protein with the addition of multiple
epitope insertion sites to increase the resultant antigen to
vector ratio (8). These truncated capsomeres were, however, less
effective at inducing of antibody responses and required co-
administration with adjuvants (7, 8, 23) including nanoparticles
such as silica, poly (D,L-lactic-co-glycolic acid) (PLGA) and poly
caprolactone (PCL) (23, 24). In another study, it was shown that
antibody responses induced by capsomeres could be enhanced
to levels similar to those of VLPs without adjuvants, but this
required a 20–40 times increase in the capsomere dose (7, 25).
However, IFN-γ cellular responses induced by capsomeres
were similar to those of VLPs, even at low doses in a HPV16
L1 model (25). Additionally, both HPV16 L1 VLPs and their
component capsomere induced robust cytotoxic CD8+ T cell
responses which were capable of tumor regression in the absence
of adjuvants (26).
Herein, we extended those studies to comprehensively
compare chimeric murine polyomavirus VLP and capsomere





(28) T cell and B cell repeat epitopes (29) from PyCSP
for capacity to induce robust CD8+ and CD4+ T cell responses
and antibody responses. In addition, we evaluated the potential
benefit of co-administration of poly(I:C) adjuvant with VLPs,
and of including a heterologous DNA prime-boost regimen.
MATERIALS AND METHODS
Oligonucleotides, Peptides and Plasmid
DNA
For genomic insertion of epitopes into VLPs and
capsomeres, complementary oligonucleotides for the
PyCSP CD8+280−288 T cell (SYVPSAEQI), CD4
+
59−79 T
cell (YNRNIVNRLLGDALNGKPEEK), and B cell repeat
(QGPGAPQGPGAP) peptide epitopes were codon-optimized
for E. coli expression then synthesized by GeneWorks
(Adelaide, Australia).
For peptide stimulation in T cell assays- PyCSP CD8280−288
(SYVPSAEQI), CD459−79 (YNRNIVNRLLGDALNGKPEEK)
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and B cell (QGPGAPQGPGAP) peptides were purchased from
Mimotopes Pty Ltd (Victoria, Australia).
For plasmid DNA immunizations, plasmid DNA encoding
full-length PyCSP (pVR2516) or empty vector without insert
(pVR1020; Vical Inc, CA, USA) were commercially purchased
from PureSyn Inc. (Malvern, PA, USA).
Plasmid Construction
The plasmid pGEX-4T-1 (GE Healthcare Biosciences, UK) with
the murine polyomavirus VP1 sequence (accession number
M34958) was obtained from the Protein Expression Facility
(PEF, University of Queensland). For the VLP platform, the VP1
sequence was modified by PEF by inserting an AfeI restriction
enzyme site flanked with Glycine4-Serine linker sequences at
position 293; this was designated pGEX-VP1-S4-G4S (7). For the
capsomere platform, the VP1 sequence was truncated to remove
the first 28 and last 63 amino acids, and restriction enzyme sites
were inserted at positions 28, 85, 293, and 380; this construct





T cell epitopes and the B cell repeat
epitope sequences were individually inserted into the AfeI site
in pGEX-VP1-S4-G4S and into positions 28, 293 and 380 of
VP11N1C using standard molecular biology techniques and
constructs were confirmed by Sanger sequencing.
Expression and Purification of Chimeric
Capsomeres and VLPs
Wild-type pGEX-VP1-S4-G4S and VP11N1C, or the chimeric
constructs detailed above, were separately transformed into
chemically competent E. coli Rosetta DE3 pLysS bacteria
(Novagen, CA, USA). The GST-tagged VP1 proteins were
expressed by bacteria culture in Terrific Broth and expression
induced using 0.2mM IPTG and purified as previously described
(7, 20). Briefly, filtered supernatant from sonicated bacteria
were purified using a 5ml GSTrap HP affinity column (GE
Healthcare, UK), then the GST tag cleaved using thrombin
(GE Healthcare UK). Capsomeres were then isolated by size-
exclusion chromatography using a Superdex 200 10/300 GL
column (GE Healthcare, UK). Endotoxin levels were reduced to
below 5 EU/ml using Vivapure Q maxi H ion exchange columns
(Sartorius Stedim, Gottingen, Germany) (7). VP1 capsomeres
were assembled into VLPs by dialysis against an assembly buffer
(7, 20) and then against PBS (7); VP11N1C capsomeres were
dialyzed only against PBS (7). The characterization of VLPs
for this project has been previously reported (18). VLPs were
analyzed using asymmetric flow field-flow fractionation coupled
to multi-angle light scattering (AF4-MALS) and transmission
electron microscopy to assess size distribution as previously
described (30, 31).
Immunization of Mice
Female BALB/c mice (n = 5/group) aged 6–7 weeks (Animal
Resources Center, WA, Australia) were immunized three times
at 3-week intervals by (i) subcutaneous injection (s.c.) of pooled
VLPs or pooled capsomeres (pools comprising 10 µg of each
CD8, CD4 and B cell chimeric construct) on the lower back near
the base of the tail; (ii) intramuscular injection (i.m.) of plasmid
DNA (100 µg) into the anterior tibialis; or (iii) s.c. injection of
pooled peptides (pools comprising 30 µg of each CD8+, CD4+
or B cell peptide epitopes) on the lower back near the base of the
tail. Capsomeres and peptides were co-administered with 50 µg
of high molecular weight poly(I:C) adjuvant (Invivogen, USA);
and VLPs were administered with or without this adjuvant, in
parallel groups. Mice were immunized in both homologous and
heterologous prime/boost regimens involving two priming doses
of PyCSP plasmid DNA followed by a booster dose of capsomere,
VLP or peptide. Negative control groups included PBS, wild-type
capsomere with poly(I:C), or wild-type VLP with poly(I:C). The
positive control group received three doses of PyCSP plasmid
DNA. All murine experiments were approved by the QIMR
Berghofer MRI Animal Ethics Committee and were conducted
in accordance with the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes (2004).
Splenocyte Harvesting and in vitro
Stimulation
Ten days after the final immunization, spleens were harvested
and single cell suspensions generated by mechanical disruption
and red blood cell lysis. For ELISpot, cytometric bead array
(CBA) and intracellular cytokine staining (ICS) assays, 5 ×
105 splenocytes were then co-incubated with 1.5 x 105 gamma
irradiated (16,666 cGy) mouse B cell lymphoma A20 cells
(ATCC TIB-208) which had been either DNA-transfected,
peptide-stimulated, or untreated. Transfections with plasmid
DNA encoding PyCSP (pVR2516) or empty vector (pVR1020)
was achieved using the AMAXA Nucleofector system (Lonza,
Switzerland) using Kit V and program C-25 with 5 × 106
A20 cells per cuvette, following the manufacturer’s protocol.
Peptide stimulation with PyCSP CD8+ (280−288) and CD4
+
(59−79) T cell epitopes, or these peptides combined with the
B cell repeat epitope peptide. Cells were incubated in KD-
MEM media comprised of Dulbecco’s Modified Eagle’s Medium
(SAFC Global, USA) supplemented with folic acid (136 nM), L-
asparagine (32mM), L-arginine (67mM), sodium bicarbonate
(24mM), HEPES (10mM), β-2-mercaptoethanol (5 nM), L-
glutamine (1.5mM), penicillin (100 Units/L), streptomycin (100
mg/L), and 10% fetal calf serum.
IFN-γ ELISpot Assay
IFN-γ ELISpot assays were conducted as previously described
(18, 32). Briefly, MSIPS4510 multiscreen ELISpot plate (Merck
Millipore, Germany) well were pre-coated with 10µg/ml anti-
mouse IFN-γ antibodies (BD Biosciences, USA), blocked
with KD-MEM containing 10% FCS, and washed. Then
splenocyte/A20 cultures in quadruplicate were incubated at
37◦C and 5% CO2 for 40 h. Wells were washed and stained
with 2µg/ml biotinylated anti-mouse IFN-γ antibodies (BD
Biosciences, USA), followed by 1µg/ml streptavidin-HRP (BD
Biosciences, USA). The assay was developed using AEC
substrate (BD Biosciences, USA). Spots were counted using
the AID ELISpot reader system (Autoimmun Diagnostika
GmbH, Germany).
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Cytometric Bead Array
Splenocyte/A20 cultures were incubated at in 96-well U-bottom
plates in 200 µl of complete media at 37◦C and 5% CO2 for
72 h. Culture supernatant was collected and stored at −80◦C
prior to assay. Secreted IFN-γ, TNF, IL-1β, IL-2, IL-4, IL-5, IL-
6, IL-10, IL-12p70, and IL-13 cytokines were analyzed using the
mouse cytometric bead array flex kit (BD Biosciences, USA)
following the manufacturer’s protocol. Samples were acquired
using a FACSArray instrument (BD Biosciences, USA) and data
analyzed using the CBA array software (BD Biosciences, USA).
Intracellular Cytokine Staining
Splenocyte/A20 cultures in 200 µl of complete media
supplemented with 0.1% Golgi Plug (BD Biosciences, USA)
in 96-well U-bottom plates were incubated for 6 h at 37◦C and
5% CO2. Cells were stained with PE-Cy7 labeled anti-CD8
+ (53-
6.7) and BV510 labeled anti-CD4+ (RM4.5) antibodies before
being fixed with 4% paraformaldehyde at room temperature
(RT) for 15min. Cells were then washed with permwash and
stained with APC-labeled anti-IFN-γ (XMG1.2), PE-labeled
anti-IL-2 (JES6-5H4) and FITC-labeled anti-TNF-α (MP6-
XT22) antibodies diluted in Cytofix/Cytoperm (BD Biosciences,
USA). All antibodies were purchased from Biolegend with the
exception of anti-TNF-α which was purchased from eBioscience.
Flow cytometric analysis was performed on a Fortessa 4 (BD
Biosciences, USA). Post-acquisition data analysis was performed
using FlowJo software version 10 (Treestar, USA).
ELISA
Sera was collected from mice 14 days after immunizations 1 and
2, and 5 days after the final immunization. Nunc Maxisorp plates
(Thermo Fisher Scientific, USA) were coated overnight with
either PyCSP B cell repeat peptide linked to a polystyrene binding
tag (33) with a glycine4 spacer (34) (Mimotopes, Australia)
(5µg/ml) or PyCSP recombinant protein (1µg/ml) diluted in
carbonate buffer. Wells were subsequently blocked with PBS
containing 2% BSA. Triplicate wells of 2-fold serially diluted
sera in PBS-BSA 0.1% were used for endpoint titrations, and
sera diluted 1:400 for isotype screening. For IgG responses, wells
were incubated with biotinylated donkey α-mouse IgG antibodies
(Jackson ImmunoResearch Laboratories, USA) diluted 1:20,000
in PBS-BSA 0.1%, followed by incubation with streptavidin-HRP
(BD Biosciences, USA) diluted 1:1,000 in PBS-BSA 0.1 and 0.2%
Tween20. For IgG isotype responses, wells were incubated with
HRP-conjugated goat anti-mouse IgG1, rabbit anti-mouse IgG2a,
goat anti-mouse IgG2b, or goat anti-mouse IgG3 antibodies
(Invitrogen, USA) all diluted 1:3,000 in PBS-BSA 0.1 and
0.2% Tween20. Wells were developed with tetramethylbenzidine
(TMB) and stopped using TMB stop reagent (Sigma Aldrich,
USA). Absorbance was measured at 450 nm using a VersaMax
microplate reader (Molecular Devices, USA). Positivity was
defined as OD450 value>3× standard deviations above the mean
blank (no serum) values.
Indirect Fluorescence Antibody Test (IFAT)
Sporozoite-specific antibodies were assayed by Indirect
fluorescence antibody test (IFAT) using a protocol modified
slightly from that previously described (35). Briefly,
cryopreserved P. yoelii 17XNL sporozoites (Sanaria Inc., MD,
USA) were centrifuged at 10,000× g for 5min then resuspended
to 105 sporozoites per ml of Medium 199 (Life Technologies,
USA). Then, 10 µl was added to wells drawn on a microscope
slide using a Barrier Pap pen and air dried at RT before long-term
storage at −80◦C. Prior to use, slides were thawed to RT in a
desiccator cabinet. Pooled sera from each immunization group
collected 5 days after the final immunization was diluted 1:400
in PBS with 2% BSA, then 10 µl was added to each well and
incubated at 37◦C in a humid box. Wells were gently washed
with PBS then stained with 10 µl of FITC conjugated anti-mouse
IgG antibodies (BD Biosciences, USA), diluted 1:30 in filtered
PBS containing 0.005% Evans blue. Slides were incubated for
30min in a humid chamber and then washed gently with PBS.
A cover slide was mounted over PBS with 10% glycerol and
slides viewed on an EVOS fluorescence microscope (Advanced
Microscopy Group, USA) at x400 magnification.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism version
6.0 (GraphPad, CA, USA). Logarithmic transformed data
of groups were compared by one-way analysis of variance
(ANOVA) and Bonferroni’s multiple comparison test. Statistical
significance is reported as ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001,
and ∗∗∗∗p < 0.0001.
RESULTS
Capsomere and VLP Construction
The genomic insertion of PyCSP peptide epitopes into the
murine polyomavirus VP1 protein for generation of VLPs (7)
or within the truncated VP1 proteins for capsomeres (8) was
confirmed by Sanger sequencing. Size exclusion chromatography
fractions post-GST cleavage showed the formation of capsomeres
as previously described (8), and these were subsequently used
for capsomere immunizations. The VLP forming proteins were
assembled in vitro and analyzed by AF4-MALS analysis, which
showed the mean radius of the chimeric VLPs [wild-type, 21.00
± 1.27 nm; CD8 VLPs, 20.51 ± 0.67 nm; CD4 VLPs, 21.07
± 0.61 nm; B cell VLPs, 20.85 ± 0.67 nm (mean radius ±
SD)] with minimal amounts of aggregation (18). Transmission
electron microscopy showed similar morphology between all
VLP groups (18).
Capsomeres Induce Similar CD8+ T Cell
IFN-γ Responses to VLPs
Significant antigen-specific IFN-γ responses were induced by
homologous immunization with both capsomeres andVLP, when
compared to their respective negative control, as detected after
in vitro stimulation with PyCSP DNA transfected A20s or with
pooled PyCSP peptides (Figure 1A). The amount of detected
IFN-γwas not significantly different between capsomeres or VLP
immunized groups (p > 0.05). The peptide immunizations also
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FIGURE 1 | IFN-γ ELISpot responses induced by chimeric VLP or capsomere constructs. BALB/c mice (n = 5/group) received three immunizations with either (A)
homologous s.c. injections of VLPs ± poly(I:C), capsomeres or peptides with poly (I:C), or (B) a heterologous DNA prime/boost regimen with two i.m. PyCSP plasmid
DNA primes followed by a single s.c. boost with VLPs ± poly(I:C), capsomeres or peptides with poly (I:C). Seven days after the final immunization splenocytes were
harvested and single-cell suspensions were stimulated in vitro for 40 h with irradiated A20 cells transfected with PyCSP plasmid DNA, or with irradiated A20 cells
pulsed with either CD8 (280−288), or CD4 (58−79) peptides or a pool of both peptides plus the B cell repeat peptide. IFN-γ spot forming cells (SFCs) were quantified with
data displayed as mean SFCs per 106 splenocytes plus SEM. Statistical comparisons made to the PBS control group and between immunization groups with
significance determined using one-way ANOVA followed by Bonferroni’s post-test. **p < 0.01, ***p < 0.001, and ****p < 0.0001.
induced a robust IFN-γ responses which was dominated by the
CD4 peptide stimulation.
Heterologous prime/boost immunization resulted in an ∼5-
fold increase in IFN-γ responses over the homologous regimens
for both capsomeres and VLPs (Figure 1B). When compared
to their homologous respective counterparts, the numbers of
IFN-γ spot forming cells in the heterologous DNA prime/boost
immunized mice were increased significantly for capsomeres (p
< 0.001), VLPs and VLPs with poly(I:C) (p < 0.0001) when
stimulated with the whole PyCSP antigen transfected into A20
cells, and capsomeres (p < 0.01), VLPs and VLPs with poly(I:C)
(p < 0.0001) when stimulated in vitro with pooled peptides.
This increase in IFN-γ responses was driven by the DNA
prime as evidenced by comparison of the responses to those of
DNA only immunized mice. Consistent with results from the
homologous immunization regimens, IFN-γ responses induced
by capsomeres and VLPs in the heterologous DNA prime/boost
regimen were not significantly different.
To differentiate the responses observed with the pooled
peptide stimulation in vitro, we also stimulated with either PyCSP
CD8+ or CD4+ T cell peptides separately. That study showed
that both the capsomere and VLP induced IFN-γ responses
were predominantly associated with the CD8+ T cell peptide,
with no significant difference between the capsomere and VLP
immunized groups (Figures 1, 2). ICS was used to determine
whether the CD8+ or CD4+ T cells were responsible for the
production of IFN-γ (Figure 3). For both PyCSP capsomere
and VLP immunized mice, IFN-γ was predominantly produced
by CD8+ T cells. Similarly, in the heterologous prime/boost
regimen, responses were directed against the CD8+ T cell epitope
and apparently driven by the DNA component with responses
similar to that induced by homologous DNA only immunization.
Capsomeres Induce More Robust CD4+ T
Cell IFN-γ Responses Than VLPs
Although capsomere and VLP platforms induced a very
similar profile of CD8+ T cell responses, unexpectedly,
they differed in ability to induce antigen-specific CD4+ T
cell responses. Specifically, homologous capsomeres induced
significantly higher IFN-γ responses than VLPs with poly(I:C)
(p < 0.0001) when stimulated with the CD4+ T cell peptide
(Figure 1A). This trend was also evident in the CBA analysis
(Figure 2) and in the CD4+ T cell response detected by ICS
(Figure 3), although the responses did not reach the level of
significance. As observed for the CD8+ T cell response, the
heterologous prime/boost was more effective than homologous
immunization in inducing robust responses to the CD4+ T
cell epitope (Figures 1B, 2). With this heterologous regimen,
which included two priming doses of DNA, the vaccine-induced
CD4+ T cell response for capsomeres and VLPs were comparable
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FIGURE 2 | Cytometric bead array analysis of antigen-specific cytokine responses induced by immunization with chimeric VLPs or capsomeres. BALB/c mice (n =
5/group) were immunized with either a homologous (no DNA prime) or heterologous (DNA prime-boost) regimen as described in the legend to Figure 1. Seven days
after the third immunization splenocytes were harvested and single cell suspensions stimulated with either the CD8+ (280−288), or CD4
+
(58−79) T cell peptides or with
pooled peptides including both peptides plus the B cell repeat peptide and incubated for 72 h at 37◦C and 5% CO2. Culture supernatant was assayed using a
cytometric bead array to quantify IFN-γ, TNF, IL-2, and IL-6 cytokine levels. Data are displayed as mean pg/ml + SEM for each cytokine with statistical comparisons
made to the PBS control group with significance determined using one-way ANOVA followed by Bonferroni’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001,
and ****p < 0.0001.
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FIGURE 3 | Flow cytometry frequency of stimulated splenocyte CD8+ and CD4+ T cells expressing IFN-γ and TNF post-immunization. BALB/c mice (n = 5/group)
received three immunizations with either homologous (No DNA prime) or a heterologous DNA prime-boost regimen (DNA prime) as described in Figure 1. Seven days
after the final immunization splenocytes were harvested and single-cell suspensions were stimulated in vitro by culturing them with irradiated A20 cells either
transfected with PyCSP plasmid DNA or pulsed with PyCSP CD8+ and CD4+ T cell and B cell repeat peptides and incubated in for 1 h before adding Golgi Plug
followed by a further 5 h incubation. Cells were stained for CD8 and CD4 receptors, then permeabilized and stained for IFN-γ and TNF cytokines then assessed by
flow cytometry. The frequency of CD8 or CD4 positive cytokine-expressing cells are shown as the group mean + SEM (n = 5 mice/group) with CD8+ and CD4+ T
cells represented by solid black bars or open bars, respectively. Statistical comparisons made to the PBS control group with significance determined using one-way
ANOVA with Bonferroni’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
and did not differ significantly from that of three doses of
PyCSP plasmid DNA alone. Nonetheless, the highest IFN-γ
responses to the CD4+ T cell peptide were seen with homologous
immunization with pooled peptides with poly(I:C) showing
beneficial effects of the repeat peptide doses.
Multiplexed Cytokine Responses
A broader spectrum of cytokine responses, including TNF, IL-2,
and IL-6 as well as IFN-γ, were quantified in culture supernatant
from in vitro immune assays using cytometric bead array
(CBA) (Figure 2). The IFN-γ response profile was consistent
with that detected by ELISpot (Figure 1). IFN-γ responses
induced by capsomeres and VLPs were comparable and directed
predominantly against the CD8+ T cell peptide, whereas the
CD4+ T cell peptide stimulated cytokine profile observed by
CBA was higher for capsomeres than for VLPs although these
differences were not significant.
Capsomeres did not induce a TNF response for either the
CD8+ or CD4+ peptide, but significant TNF responses were
induced by VLP immunization and this was further increased by
poly(I:C) adjuvant; these responses were preferentially directed
against the CD8+ T cell peptide but were also significant for the
CD4+ T cell peptide epitopes (Figure 2).
Significant IL-6 responses were induced by both capsomere
and VLP groups with or without DNA priming, with a similar
profile for both CD8+ and CD4+ T cell peptide epitopes.
In the peptide-immunized mice, responses for robust for IFN-
γ, TNF, and IL-6 cytokines were preferentially directed to the
CD4+ T cell peptide.
Negligible IL-2 levels were induced by any of the vaccine
platforms tested (capsomeres, VLPs, or peptide) as assessed by
ICS (data not shown) and CBA (Figure 2). The IL-1β, IL-4, IL-5,
IL-10, IL-12p70, and IL-13 cytokine responses detected by CBA
were also very low and no differences were identified between the
two platforms (data not shown).
Frontiers in Immunology | www.frontiersin.org 7 September 2020 | Volume 11 | Article 564627
Pattinson et al. Capsomere and VLP Induced Immunogenicity
FIGURE 4 | PyCSP-specific antibody responses induced immunization with
chimeric VLPs or capsomeres. BALB/c mice (n = 5/group) were immunized
with DNA, VLP, capsomeres or peptides in a three-dose homologous regimen
or a heterologous DNA prime boost regimen as described in Figure 1. Sera
collected 14 days after each immunization and 5 days after the final
immunization were analyzed either individually or pooled, by ELISA using the
(Continued)
FIGURE 4 | PyCSP B cell repeat epitope linked to a polystyrene binding tag
(A–C,E) or PyCSP protein (D) as capture antigen. (A) B cell epitope-specific
endpoint total IgG antibody titres for individual mice with sera collected after
the final immunization. Data is shown as mean ± SEM for each group. (B) B
cell epitope-specific endpoint total IgG antibody titres for pooled sera collected
following each immunization. (C) B cell epitope-specific IgG1, IgG2a, IgG2b,
and IgG3 antibody isotype responses for pooled sera collected after the final
immunization. Data is shown as a cumulative OD450nm readout. (D) PyCSP
antigen-specific endpoint total IgG antibody titer for pooled sera collected after
the final immunization. (E) B cell epitope-specific IgG3 antibody responses for
individual mice with sera after the final immunization. Data are for individual
mice are shown as OD450 values with bars representing the group mean.
Inter-group significance was determined using one-way ANOVA followed by
Bonferroni’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
0.0001.
Capsomeres Were Less Efficient Than
VLPs at Inducing Antibody Responses
ELISA assays against the PST-PyCSP B cell repeat peptide and
PyCSP recombinant protein were performed using individual
and pooled mouse sera collected 14 days after doses 1 and
2; and 5 days after final immunization (Figure 4). Consistent
with previous studies, VLPs induced high anti-PyCSP B
cell repeat IgG titres which were increased with the co-
administration of poly(I:C) adjuvant (Figure 4A). Capsomeres
inducedmoderate titres but, importantly, these were significantly
less than VLPs with and without poly(I:C) (p < 0.01 and p
< 0.05, respectively). There was a trend to increased antibody
response with VLP administered with adjuvant compared to the
non-adjuvanted VLPs but this was not statistically significant.
However, the adjuvant effect was significant when VLPs were
administered with a DNA prime (p < 0.05) indicating that
with only a single VLP dose, the inclusion of adjuvant is
beneficial and this benefit becomes less important after multiple
doses (Figure 4B). A priming dose of DNA appeared to
adversely affect the antibody induction, since responses in the
heterologous prime-boost regimen tended to have lower titres
than their homologous counterparts especially in the absence of
poly(I:C) (p < 0.01).
We assessed the anti-PyCSP B cell peptide total IgG
responses using pooled sera collected after each immunization
to determine the effect of the number of immunizations within
each regimen (Figure 4B). After each dose of VLPs, there was
a trend to increased antibody titres when poly(I:C) adjuvant
was co-administered.
Antibody isotypes contributing to the total IgG response
reported above were also delineated, using pooled sera collected
after the final immunization (Figure 4C). Immunizations with
capsomeres, VLPs and VLPs with poly(I:C) each induced robust
IgG1 responses which were similar for all groups, and the
IgG2 response in the VLP-immunized mice was increased
when administered with poly (I:C). VLP immunizations induced
an IgG3 response which was absent in the capsomere-
immunized mice. Compared to other immunization regimens,
the homologous VLP immunization groups had higher levels
of IgG3 but similar levels of IgG1 indicating that the second
and third doses caused a shift in isotype responses toward an
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IgG3 bias. IgG2a responses were increased with the inclusion of
poly(I:C) with the VLP but this was not present in the capsomere
with poly(I:C) immunized mice, indicating the difference was
platform specific. Moderate IgG2a responses were also present in
the DNA group and the heterologous DNA prime groups.
To confirm that the vaccine-induced antibodies had affinity
to the PyCSP protein, pooled sera collected after the final
immunization was assayed using ELISA against recombinant
protein (Figure 4D). The endpoint titres and profile were similar
to that reported above for the B cell peptide (Figure 4A).
To confirm that the IgG3 response was consistent within
groups, an ELISA against the PyCSP B cell repeat peptide
was done using individual sera (1:400) collected after the
final immunization (Figure 4E). Each VLP immunization group
tested had significant amounts of IgG3 which was absent in
chimeric capsomeres. The inclusion of poly(I:C) resulted in
increased levels of IgG3 responses, and the homologous three-
dose regimen significantly increased levels as compared to the
heterologous prime/boost regimen (p < 0.001).
Antibody Recognition of Native Antigens
Importantly, antibodies induced by immunized with capsomeres
or VLPs with or without poly(I:C) adjuvant were able to
recognize P. yoelii 17XNL sporozoites, as evidenced by surface
staining in the homologous and heterologous immunization
regimens (Figure 5).
DISCUSSION
The Plasmodium sp. CSP is the leading antigen target for sub-
unit vaccines against malaria, and is the antigenic component of
the virus-like particle RTS,S which is the most advanced human
vaccine candidate against Plasmodium falciparum malaria. It
was, therefore, a logical choice for evaluation of novel vaccine
delivery platforms. We know that liver-stage protection from
sporozoite challenge can be achieved by either CD8+ T cells
(27, 36, 37), CD4+ T cell (38, 39) or antibody responses (29, 40).
Thus, herein, we constructed chimeric VLPs and capsomeres
incorporating a CD8+ T cell epitope, CD4+ T cell epitope, or B
cell epitope derived from PyCSP in order to evaluate and compare
the ability of capsomeres and VLP vaccine platforms to induce
epitope-specific cellular and antibody responses.
Although the antibody-inducing capacity of chimeric murine
polyomavirus VLPs and capsomeres has been well-established
(7–9, 23), the ability of this vaccine platform to induce epitope-
specific T cell responses has not previously been comprehensively
evaluated. We set out to accomplish this. Our study established
that capsomeres and VLPs induced similar and significant levels
of antigen-specific IFN-γ responses and these responses were
primarily directed against the immunodominant PyCSP CD8+
T cell epitope and produced by CD8+ T cells. This CD8+ T cell
IFN-γ immune response is considered essential for protection
(39, 41). Moreover, responses were increased when DNA priming
was included as a heterologous regimen, as expected based on
previous studies (18, 42–44). Interestingly, however, while both
platforms were similar in capacity to induce an IFN-γ response,
it was only the VLPs which evoked a TNF response, albeit at low
levels, suggesting that VLPs may be better than capsomeres at
inducing polyfunctional T cell responses.
In contrast to the comparability of the CD8+ T cell responses,
VLPs and their subunit capsomeres differed significantly in
capacity to induce CD4+ T cell responses and antibody
responses. Unexpectedly, capsomeres proved to be the best
platform at inducing responses to the CD4+ T cell epitope.
The target PyCSP CD4+ T cell epitope (59−79) was selected for
study because of its the ability to induce functional CD4+ T cell
populations of either TH1 or TH2 subsets associated with T cell
proliferation responses or help for antibody responses (28). In
our previous study, we could not detect any synergistic CD4+
T cell helper effect on antibody titres by co-administering a
chimeric CD4 VLP (in a VLP pool) with B cell VLPs (18). In the
current study, we were unable to show any CD4+ T cell helper
responses as both capsomeres and VLPs were only administered
in pools. We found that immunization with pooled peptides
adjuvanted with poly(I:C) induced the most robust responses,
however this is likely related to the dose of the target peptide
epitope, as the positive control peptide pools incorporated 30 µg
of the CD4 peptide whereas the amount of epitope presented
in the chimeric capsomeres and VLPs was ∼1.77 and 0.52 µg,
respectively, per dose. This may also explain why the capsomeres
were more effective than VLPs at inducing responses against
this peptide epitope as one of the benefits of capsomeres over
VLPs as a vaccine platform is the ability to present a higher
antigen load, and in our study capsomeres achieved a 3-fold
higher antigen dose than VLPs. It should be noted that the
antigen dose difference was the same for the CD8+ T cell peptide
epitope and we did not see similar increased immune responses
against that antigen target. The ability of capsomeres to induce
CD4+ T cell responses is an important advantage for vaccinology
since vaccine platforms that preferentially induce CD8+ T cell
responses rather than antibody responses are often poor inducers
of CD4+ T cell responses (45). The essential role of CD4+ T
cells for vaccine-induced protection against malaria has been
demonstrated in CD4+ T cell-depleted sporozoite-immunized
mice where an absence of CD4+ T cells resulted in reduced anti-
sporozoite antibodies, a reduced effector capacity of CD8+ T
cells, loss of protective efficacy (46).
It is well-established that VLPs are very effective at inducing
antibody responses, perhaps due to their ability to cross-link B
cell surface receptors (25) acting in a T cell independent manner
(47, 48). Indeed, for all licensed VLP-based vaccines, protection is
thought to be mediated through neutralizing antibodies (10, 11).
Furthermore, studies using VLPs as well as their capsomere
components with adjuvants showed them to be strong inducers
of antibodies to inserted antigens (7–9, 23). Here, we have shown
that VLPs with and without adjuvant were significantly better
than capsomeres at inducing antigen-specific antibody responses,
and that inclusion of poly(I:C) adjuvant increased antibody
titres (49) with a skewed TH1 isotype profile. Importantly, these
vaccine-induced antibodies were capable of recognizing the B
cell repeat peptide, as well as recombinant PyCSP protein, and
the parasite and IFAT showed antibody affinity to the surface
of sporozoites establishing that they could recognize the whole
parasite as well as the protein. The durability of the induced
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FIGURE 5 | IFAT detection of anti-sporozoite antibodies induced by immunization with chimeric VLPs or capsomeres. Mice (n = 10/group) were immunized using a
three-dose regimen with either homologous VLPs, capsomeres or PyCSP plasmid DNA; or a heterologous regimen with two PyCSP plasmid DNA doses followed by
a single VLP or capsomere boost as described in Figure 1. Sera collected from mice 5 days after final immunization was pooled and assayed against P. yoelii 17XNL
sporozoite-coated slides (1:400 dilution). Slides were stained using FITC-conjugated anti-mouse total IgG and viewed on an EVOS fluorescence microscope at x1000
magnification. Scale bar represents 10µm.
antibodies and their protective capacity has yet to be established.
The value of anti-CSP antibodies has been shown by their ability
to sterilely protect mice against sporozoite challenge (29), and
by observations that anti-CSP IgG concentration and avidity
contribute to RTS,S/AS01E-mediated protection (50) with anti-
CSP antibodies estimated to prevent 32% of infections following
RTS,S immunizations (51).
An interesting observation from our study is that the IgG3
antibody isotype observed with VLP immunizations contrasts
with results obtained using the same platform incorporating the
Group A Streptococcus J8 peptide, where IgG1 was the dominant
IgG isotype and no IgG3 was detected (7). It appears, therefore,
that the development of IgG3 is associated with the target epitope
presented in the VLP structure rather than with the VLP platform
itself. We had previously observed that an IgG3 response was
induced by immunization with three doses of chimeric B cell
epitope VLPs alone (our unpublished data), establishing that
the CD8+ or CD4+ T cell chimeric VLPs were not responsible
for the subclass, as seen in other platforms (52). It is curious
that the IgG3 response was induced by immunization with
VLPs but not capsomeres. IgG3 antibodies have previously been
identified as important for protection against various pathogens
(53, 54) including Plasmodium spp. parasites (35, 40), and
IgG3 monoclonal antibodies raised against the PyCSP repeat
(QGPGAP) protected BALB/c mice from a P. yoelii 17XNL
sporozoite challenge (29).
There are many examples of enhanced immunogenicity
and protection with DNA prime-boost regimens using various
antigen delivery systems encoding the same antigen or epitope
(44, 55–58) including VLPs (59) as a boost immunogen.
Consistent with those reports, our data shows that the
heterologous prime-boost regimen was better at inducing cellular
responses than a homologous immunization regimen, for both
capsomere and VLP platforms. The gain in cellular responses
observed by including a plasmid DNA prime was, however,
countered by a decrease in antibody titres. This is consistent
with the known ability of plasmid DNA to preferentially prime
a CD8+ T cell response and its poor ability to prime an antibody
response (45).
Chimeric capsomeres are a promising vaccine platform which
build on the established vaccine potential of VLPs, but are
easier and cheaper to produce than VLPs (22), and can include
more antigenic insertion sites because there is no reliance on
structural VLP formation. Here, we show that capsomere and
VLP platforms induced similar levels of CD8+ T cell responses
but the capsomeres were significantly better at inducing epitope-
specific CD4+ T cell responses than VLPs. This enhanced CD4+
T cell response may be of particular importance in the control
of chronic viral infections (60), the maintenance of CD8+ T
cells during prolonged viral infections (61) where CD4+ T cell
help may be required for optimal CD8+ T cell activity (62) or
for CD8+ T cell memory (63), or indeed for optimal responses
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against any pathogens where a CD4+ T cell vaccine induced
response is required. On the other hand, since capsomeres have a
limited capacity to induce antibody responses, VLPs would be the
preferred platform for antibody mediated immunity. Given that
most licensed vaccines target the induction of antibody response
and the increasing interest at identifying vaccine platforms
capable of inducing robust T cell responses, our data have
important implications for the development of vaccines against
those pathogens that have thus far proved challenging.
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